FDA Committee Recommends Hospira’s Epogen/Procrit Biosimilar for Approval

Drug Industry Daily
A A
An FDA advisory committee endorsed Hospira’s biosimilar version of Epogen and Procrit, used to stimulate the production of red blood cells.

To View This Article:

Login

Subscribe To Drug Industry Daily